J&J says Phase 3 FUZION trial shows TREMFYA delivers up to 28% perianal fistula remission in Crohn’s disease
Johnson & Johnson disclosed new Phase 3 subgroup data for TREMFYA in Crohn’s disease patients with perianal fistulas. Results were being presented at the American College of Gastroenterology 2026 Annual Scientific Meeting. TREMFYA delivered consistent fistula remission outcomes across difficult-to-treat groups, includi